James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).
James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain genetic abnormalities for which a targeted drug exists.
Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).
Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pertuzumab, and neratinib (Abstracts 505 and 508).
